RSS

CYDY CytoDyn Inc

Mod: mightycydy Asst: HHIGambler,CaptnAmerca
Last Post: 8:03 AM
Followers: 439
Posts Today: 2
Views Today: 68245

CYDY Stock Quote & Tools

$0.2054 ▲ +0.0054 (+2.69%) As of Oct 15, 3:59 PM EDT
Last0.2054
$ Chg0.0054
Open0.2000
High0.2090
Beta1.4964
Year High0.397
Market Cap301.80M
P/B Ratio-2.68
EPS-0.04
Avg Vol (30d)1.57M
Volume3.28M
% Chg+2.69%
Prev Close0.2000
Low0.1971
VWAP0.20198
Year Low0.183
Total Shares1.47B
Shares Out1.47B
Float1.36B
ExchangeOTCQB
Healthcare Biotechnology & Life Sciences
Company Profile Buy Rating Time & Sales News Filings Financials

CYDY Stock Message Board Discussion

3 Pinned Posts
Leronlimab (Pro 140) Cliff Notes What is it? Leronlimab is a humanized monoclo (43) by trding
Leronlimab Regulator List (a work in progress) = upregulation = downregulation a-SMA (21) by ohm20
EIND: Information to Submit to Doctors Leronlimab a humanized monoclonal antibody binds CCR5, (38) by ohm20
  1. Figgs

    But a useless therapeutic is perfect so we can continue the vaccine push and if a new variant beats

    (2)
  2. Normy

    When i see what has happened with all the political back tracking and revised theories on all kinds

    (9)
  3. CaptnAmerca

    This feels like they said, let's get something useless like convalescent plasma, but really

    (4)
  4. Normy

    "just a shot and you feel better in a couple of days" The Leronlimab saga is just chapter 32

    (2)
  5. CaptnAmerca

    LOL. Who do you think told the FDA to get him something on Alzheimers? He just made a speech

    (3)
  6. sean007

    Big takeaways from the study suggest the olfactory system is a major route of infection to the

    (2)
  7. Enjay

    Sen. Manchin to Biden: Don't nominate Woodcock for FDA commissioner While Sen. Joe Manchins

    (7)
  8. sean007

    MAYBE if someone alerts them to our CC...Black health Trust and Downstate Medical Center and (SUNY)

    (3)
  9. sean007

    With some (investors)?... the "lack of Due Diligence is staggering."

    (2)
  10. sean007

    The FDA's mission statement is "to protect the American Public from Toxic drugs with adverse

    (7)
  11. craigakess

    LOL...no, not getting soft, and if read without emotion, most of my posts ARE actually leaning

    (4)
  12. Kevin0461

    Geez Craig that was almost a positive post sort of. Are you getting soft on

    (6)
  13. craigakess

    I would say "yes" to all that you asked, but then say look at all of the promises we thought would

    (5)
  14. Babaji

    Brain damage paper tracing Covid-19 impact via pre and post imaging.

    (3)
  15. PTM1

    The real question is, have we found the Holy Grail? The correct answer is maybe

  16. jeff67

    Yes, my question is will they have any avenue to getting Vyrologix now that their trial is over.

    (4)
  17. MarcS

    Why would they release LH data on the Monday before the 1st International Symposium on COVID-19

    (4)
  18. ohm20

    If the trial results are not good enough to start a phase 3 trial Have you even

    (19)
  19. dfwl28

    "I wonder if insurance companies will cover this Alz drug in the face of the outspoken objections

    (3)
  20. AeroDude

    Very true. If the trial results are not good enough to start a phase 3 trial, then HIV BLA will

    (5)
  21. Hyperbolic

    Agreed. As a near 6 year investor I have seen countless proactive videos and listen many conference

    (8)
  22. stevo180

    LL blocks CCR5 , nothing about that has change since i've owned this stock. What I do see thats

    (5)
  23. Goosebumps

    The point is not the FDA setting a price. The NIH or any other government departments granting

    (1)
  24. fsoalex

    According to CDER, the FDA has no legal authority to set drug prices. The message is

  25. ohm20

    4) BLA fiasco: comments: is it syringes or RO or spreadsheet formatting? Perhaps

    (3)
  26. Evil Rabbit

    My hope for Monday's CC is Terra Firma. I will start to relax if we get into

  27. havasu78

    I would describe the following public comments by Cytodyn as both blithering and idiotic: !)

    (13)
  28. chazzledazzle

    My hope for Monday's CC is Terra Firma.

  29. bigO

    Impressive!

  30. VegasorBust

    https://apple.news/AkgUK4qTbQxCnqsACgLPNSg Sounds like she took her own life after dealing with

    (3)
  31. swordman

    FYI--

    (3)
  32. Shelly2626

    Awesome post Thank you!!!! GLTA

    (1)
  33. ohm20

    I've just recently started to build that list, which I should have been doing when I was first

    (2)
  34. ohm20

    From what I know of when possibly the last patient was injected, lock could have been on June 13th.

    (4)
  35. ohm20

    Leronlimab is a triple threat there. Use it for immunomodulation in transplant patients instead of

    (6)
  36. CTMedic

    Ohm, How about MMP-10? Strongly linked to brain fog/cognitive dysfunction in a host of

  37. ohm20

    Tofacitinib is a selective inhibitor of JAK1 and JAK3 We've got that covered. l

    (7)
  38. ydyc

    What are you implying? I wouldn't be suprised if they end up having to beg the FDA lol Can those

  39. jeff67

    What happens to the current group of people in this trial who turn out not to be on placebo and

  40. nicehedges

    Dr. Norman Gaylis tweets: https://i.imgur.com/oAR4mwI.png

    (21)
  41. Evil Rabbit

    Cytodyn would have the results before the clinic and likely wouldnt tell Gaylis staff until

    (8)
  42. generactor

    But the PR said, "management will provide a full discussion of the results from the recently

    (1)
  43. nmbr1stckpckr

    Good results on Monday will make enrolling for ph3 even easier than it was for ph2. Everyone will

    (6)
  44. sean007

    Your approach would suggest you are better suited to "critique their investment"...you should have

    (2)
  45. sean007

    Of note was the reference to transplant patients ...who are particularly susceptible after surgery.

    (2)
  46. sean007

    I would take exception to characterizing our doctors as "blithering idiots"...how are you

    (4)
  47. sean007

    "IFF anyone is interested"...is such an odd way to offer services... a back-handed way of

    (1)
  48. CDiddy

    My question is how many people will we have to enroll to complete a phase 3 that the FDA

    (3)
  49. ydyc

    Yes it is good knowing that enrollment should be moving right from the start of the LH trial. NP

  50. CDiddy

    That would be nice. I'm trying to keep my expectations tempered, as I have allowed myself to get

    (5)

Top 10 Most Recent News Articles

More News Articles

Top 5 Most Recently Viewed Articles

Carlisle Companies Declares $1 Dividend Amid Strong Financials

Updated Category News Views 82

Carlisle Companies Announces New Dividend Carlisle Companies Incorporated (NYSE: CSL, OTC: CSLLY), a leader in building envelope products, has recently declared a dividend of $1.00 per share. This dividend aims to reward shareholders and is indicative of the company's robust financial health. By planning this payout for December, Carlisle emphasizes its dedication to...

Continue Reading
Highlights and Key Developments in Healthcare Press Releases

Updated Category News Views 215

Overview of Healthcare News The healthcare sector was abuzz with significant press releases, showcasing innovative developments and important updates. This summary aims to encapsulate the key stories that shaped healthcare discussions during the month. Noteworthy Healthcare Announcements With a flurry of impactful healthcare announcements, journalists and consumers are...

Continue Reading
Atossa Therapeutics to Lead Innovative Discussion at BIO-Europe

Updated Category News Views 162

Atossa Therapeutics and Karolinska Institute Unite for a Pioneering Discussion Atossa Therapeutics, Inc. (NASDAQ: ATOS) has announced an exciting opportunity for engagement at BIO-Europe 2024. The company’s Chairman and CEO, Dr. Steven Quay, will participate in a fireside chat alongside Dr. Per Hall, a distinguished Professor of Epidemiology from the Karolinska...

Continue Reading
PTC Therapeutics Enhances Employee Compensation with Stock Options

Updated Category News Views 183

PTC Therapeutics Approves New Employee Stock Options PTC Therapeutics, Inc. (NASDAQ: PTCT) has recently made significant strides in enhancing employee compensation by approving non-statutory stock options and restricted stock units (RSUs) for two new hires. This thoughtful incentive underscores the company's commitment to attracting and retaining talented individuals in...

Continue Reading
Einride Secures $100 Million Investment to Innovate Freight Solutions

Updated Category News Views 187

Einride Achieves Major Milestone with $100 Million Funding Einride, a pioneering technology company recognized for its innovative electric and autonomous freight solutions, has successfully secured approximately $100 million in funding. This investment marks a significant step as the company aims to enhance the deployment of its autonomous freight solutions and expand its...

Continue Reading